This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mbori-Ngacha, D.
Right arrow Articles by John-Stewart, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mbori-Ngacha, D.
Right arrow Articles by John-Stewart, G.

 Previous Article

Journal of Virology, July 2003, p. 7702-7705, Vol. 77, No. 13
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.13.7702-7705.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Short-Term Effect of Zidovudine on Plasma and Genital Human Immunodeficiency Virus Type 1 and Viral Turnover in These Compartments

Dorothy Mbori-Ngacha,1 Barbra A. Richardson,2,3 Julie Overbaugh,3 Dana DeVange Panteleeff,3 Ruth Nduati,1 Matt Steele,2 and Grace John-Stewart1,2*

Departments of Pediatrics and Medical Microbiology, University of Nairobi, Nairobi, Kenya,1 Departments of Biostatistics, Medicine, and Epidemiology, University of Washington,2 Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington3

Received 28 October 2002/ Accepted 25 March 2003

The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log10 in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions.

* Corresponding author. Mailing address: IARTP, 325 Ninth Ave., Box 359909, Seattle, WA 98104. Phone: (206) 731-2822. Fax: (206) 731-2427. E-mail: gjohn{at}u.washington.edu.

Journal of Virology, July 2003, p. 7702-7705, Vol. 77, No. 13
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.13.7702-7705.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»